Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Eli Lilly and Company, the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), has announced positive topline results from a phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes
Acute activation of central GLP-1 receptors enhances hepatic insulin action and insulin secretion in high-fat-fed, insulin resistant mice
Presented for research literature review only Huerto-Delgadillo L et al
Wegovy (higher-dose semaglutide) targets obesity, Trulicity offers simplified weekly dosing, and Ozempic, a derivative of semaglutide, remains a reliable option for efficient blood sugar control
US$ 25.93
US$ 27.09
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
US$ 24.11
US$ 29.44
